Skip to main content
. Author manuscript; available in PMC: 2017 Mar 24.
Published in final edited form as: Cell. 2016 Mar 17;165(1):35–44. doi: 10.1016/j.cell.2016.02.065

Figure 3. Co-enrichment of Innate Anti-PD-1 Resistance-associated Signatures Defines a Transcriptomic Subset in Melanoma and Multiple Cancers.

Figure 3

(A) Heatmap showing GSVA scores of IPRES signatures across four independent RNASeq data sets derived from metastatic melanoma. Cohort 1, pretreatment (anti-PD-1) tumors; cohort 2, pretreatment (anti-CTLA-4) tumors; cohort 3, pretreatment (MAPKi) tumors; cohort 4, TCGA cutaneous melanoma (metastatic only).

(B) Heatmap showing GSVA scores of IPRIM signatures across TCGA RNASeq data sets (metastatic melanoma or SKCM, lung adenocarcinoma or LUAD, colon adenocarcinoma or COAD, kidney clear cell carcinoma or KIRC, and pancreatic adenocarcinoma or PAAD).

See also Figure S3.